IOWA | Health and Human Services

# Iowa Medicaid Drug Utilization Review (DUR) Commission

**August 6, 2025**

**Hybrid Meeting**

**Location:** **Grimes State Office Building Room B 100** **Time: 9:30 a.m. – 1:30 p.m. CT**
**400 E 14th Street**
**Des Moines, IA 50319**

**Virtual Option: Zoom**
https://www.zoomgov.com/j/1607379719?pwd=Wo4vZbAdGnOQ5YCVrgfCrCb9sOsZhU.1

Meeting ID: 160 737 9719
Passcode: 338041

## Tentative Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the May 7, 2025 Meeting Minutes
    b) May 2025 DUR Recommendation Letter to DHHS
    c) April 2025 P&T Recommendation Letter
    d) Annual Chair and Vice Chair Elections
    e) Annual Conflict of Interest Disclosure
    f) Follow-Up from Previous Meeting(s)
    g) DUR Recommendation Process
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Fee-for-Service
    b) Iowa Total Care
    c) Molina Healthcare of Iowa
    d) Wellpoint Iowa
    e) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must **pre-register** to provide verbal public comment and submit a completed conflict of interest disclosure. Must indicate if will be in-person or verbal testimony. Five (5) minute maximum limit.
    - Written – Must submit written comments and a completed conflict of interest disclosure.
    - **All submissions must be received no later than 4:30 p.m. CT July 29, 2025.**
    - **Send to pba_iadur@optum.com. Indicate in email if providing written or verbal comment.**
6. Retrospective DUR
    a) Data Presentation(s)
        i. Opioid Reversal Agent Frequency in Members with MME ≥ 90
    b) Proposal(s)
        i. Risk of Hyperthermia with Scopolamine Patch
        ii. Utilization of SGLT2 Inhibitors in Members with CKD

c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR
    a) Concurrent Use of GLP-1 RA and DPP-4 Inhibitor – Second Review
8. Break (10 minutes)
9. Prior Authorization
    a) Anti-Diabetic Non-Insulin Agents
    b) Dupilumab (Dupixent)
    c) Janus Kinase (JAK) Inhibitors
    d) IL-5 Antagonists
    e) Olezarsen (Tryngolza)
    f) Omalizumab (Xolair)
    g) Palopegteriparatide (Yorvipath)
    h) Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitors – Second Review
    i) Givinostat (Duvyzat) – Second Review
    j) Lebrikizumab-lbkz (Ebglyss) - Second Review
    k) Nemolizumab-ilto (Nemluvio) – Second Review
10. Miscellaneous
    a) DUR Digest Vol. 37, No. 2 – Second Review
11. MedWatch

    FDA Alerts Health Care Providers, Compounders and Consumers of Potential Risks Associated with Compounded Topical Finasteride Products

    FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)

    FDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system)

    Updated Labeling for IBAT Inhibitors Maralixibat and Odevixibat Related to Hepatotoxicity and the Fat-soluble Vitamin Deficiency Sequela of Bleeding

    FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
12. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment must register and complete a conflict-of-interest disclosure. Registration and completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at pba_iadur@optum.com. Failure to register and submit a complete conflict-of-interest disclosure form by the specified date and time will result in a delay of your comments being considered until the next scheduled meeting. Reference complete public comment policy here.

**www.iadur.org**

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at pba_iadur@optum.com or (515) 974-3131.

**Next Meeting**
**November 5, 2025**
**Meeting Format: Virtual**